NCT06980350Completed
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
Source: ClinicalTrials.gov · Last updated 29 Jul 2025
Brief summary (registry, in English)
A novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dMMR colon cancer was developed to validated its efficacy in two independent cohorts, and to assessed its feasibility for W\&W strategy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 156 (actual)
- First submitted
- 12 May 2025
- Start date
- 1 Jul 2018
- Primary completion date
- 30 Jun 2023
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT06980350
What you commit to
- Study type: Observational
- Participants enrolled: 156
- From 1 Jul 2018 to the primary completion date, 30 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- pathologically confirmed colon adenocarcinoma;
- immunohistochemistry testing as dMMR tumors;
- received at least two doses of anti-PD-1 immunotherapy in a neoadjuvant setting.
- received radical surgery.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.